1. Hologic (NASD: HOLX) to go private in $18.3 Billion acquisition by Blackstone and TPG, Minority Stakes for Abu Dhabi Investment Authority and GIC The transaction is designed to deliver compelling value to shareholders and highlights continued innovation in women’s health and AI-driven diagnostics. Hologic will maintain its brand and headquarters while operating privately. The agreement includes a 45-day “go-shop” period, and closing remains subject to regulatory and shareholder approvals, with completion anticipated in the first half of 2026. (Link)
2. Novartis (NYSE: NVS) to acquire Avidity Biosciences (NASD: RNA) for $12 Billion; SpinCo to Emerge as Independent Cardiology-Focused Company The deal, unanimously approved by both boards, will give Novartis global rights to innovative RNA-based neuromuscular therapies and boost its neuroscience pipeline with potential first-in-class candidates. Avidity shareholders will receive additional SpinCo stock or cash linked to its cardiology assets. Regulatory and shareholder approvals are pending. (Link)
3. Eli Lilly (NYSE: LLY) to acquire Adverum Biotechnologies (NASD: ADVM) in Deal Centered on Ixo-vec Gene Therapy Lilly’s purchase will help advance Ixo-vec, a novel gene therapy for vision loss, offering shareholders potential milestone payments based on regulatory and sales goals. This late-stage treatment addresses a major unmet need for wet age-related macular degeneration. The acquisition also secures short-term funding for Adverum’s clinical progress. (Link)
4. Alkermes (NASD: ALKS) to acquire Avadel Pharmaceuticals (NASD: AVDL) for Up to $2.1 Billion, Expanding Sleep Medicine Portfolio with LUMRYZ™ Alkermes’ acquisition adds the FDA-approved LUMRYZ™, a once-at-bedtime sodium oxybate treatment for narcolepsy symptoms like cataplexy and excessive daytime sleepiness. The deal offers shareholders $18.50 upfront plus $1.50 contingent on FDA label expansion, a 38% premium over recent prices. Closing is expected in Q1 2026, enhancing Alkermes’ sleep medicine portfolio and leveraging Avadel’s expertise for future pipeline development. (Link)
5. DocGo (NASD: DCGO) acquires SteadyMD to Expand Telehealth Services Nationwide; SteadyMD Co-Founders Join Leadership Team DocGo acquired SteadyMD to expand its telehealth reach across all 50 states, integrating SteadyMD’s virtual clinician network with its mobile healthcare services. SteadyMD, expected to generate $25 million in 2025, serves over 3 million patients, including Fortune 10 clients. SteadyMD’s leadership joins DocGo’s team, and the acquisition is funded by DocGo’s cash reserves. (Link)
6. Lemonaid Health acquired by Bambu Ventures to relaunch as Independent Telemedicine Platform after Bankruptcy Lemonaid Health, after bankruptcy will pursue aggressive growth as an independent telemedicine and pharmacy platform. Bambu and Innova Partners provide executive leadership, focusing on affordable care, same-day prescriptions, and market expansion. Key board appointments and new investors support innovation and differentiation. (Link)
7. Opyn Health, Inc. acquires Empara to Integrate AI-Driven Benefits Engagement and Boost Platform for Self-Insured Healthcare Combining Opyn’s price transparency and virtual care expertise with Empara’s AI-powered app streamlines benefits administration and cost management for members and administrators. Empara’s founders join Opyn, and the unified platform will serve TPAs, brokers, and self-insured employers—aiming to replace legacy systems with a seamless digital access point for healthcare. (Link)
8. Oasis Health Partners® acquires PreferCare to Strengthen Value-Based, Preventive Primary Care for Seniors in North Carolina PreferCare enhances Oasis’s capabilities with in-home and virtual care for seniors, leveraging new tools, analytics, and clinical support. The partnership improves coordinated care, preventive screenings, and early interventions. By empowering physicians and supporting practices, Oasis advances health equity and outcomes, building healthier communities through a value-based care model. (Link)
9. Duly Health and Care acquire Woodridge Clinic, via its financial sponsors Ares Private Equity Group, Guidon Partners and Athyrium Capital Management, expanding Physician-led Primary Care Services across Chicagoland Woodridge Clinic, founded in 1986, excels in primary care, diabetes management, and occupational therapy. Joining Duly gives its team access to new resources and technology, expanding specialty care and services in Lemont, Lombard, and Woodridge. This partnership strengthens coordinated, patient-focused care for local families and supports ongoing provider recruitment. (Link)
10. Frontline Healthcare Partners acquires Integracare Inc. to drive expansion of Private-Pay Home Care across Ontario, Canada Integracare will benefit from expanded operational resources and Frontline’s healthcare investment expertise to reach new communities. The partnership preserves its focus on personalized, quality home care and workplace excellence, supporting growth beyond Toronto, Mississauga, and Ottawa. This move helps advance Integracare’s mission and expands personalized home health solutions across Ontario. (Link)
11. Cerebral raises $25 Million in Latest Funding Round, Accelerating Growth and Platform Integration The capital infusion, following the Resilience Lab acquisition, will support Cerebral’s nationwide expansion, platform integration, and quality initiatives like improved clinical training. Funds will enhance telehealth services, solidify insurance partnerships, and drive innovation in therapy, psychiatry, and medication management, as the company rebuilds after leadership and regulatory challenges. (Link)
12. Counsel Health raises $25 Million Series A Led by Andreessen Horowitz and GV to Launch Physician-Supervised AI Front Door for Healthcare Following $11 Million Seed Round Counsel Health’s platform delivers instant, context-aware medical guidance via chat or voice, using AI with physician oversight for diagnosis, prescriptions, or referrals and unlimited follow-up. It reports a 96% resolution rate, rapid response times, and measurable cost savings. Serving 100,000+ members now, it’s expanding to reach millions nationwide. (Link)
13. Faeth Therapeutics raises $25 Million, led by S2G Investments, with Support from KdT Ventures, Khosla Ventures, Future Ventures, Cantos Ventures, Digitalis Ventures, B Capital Group, Avicella Capital, THO Seed Fund and Others Faeth Therapeutics’ funding will support a randomized phase 2 trial of its PIKTOR regimen after an 80% response rate and 11-month median progression-free survival in endometrial cancer. The capital enables insulin control research, expansion into rectal cancer and rare metabolic disorders, and growth of the MetabOS™ precision oncology platform. (Link)